false
Catalog
The Lead Episode 23: A Discussion of Anticoagulati ...
New England Journal of Medicine
New England Journal of Medicine
Back to course
Pdf Summary
The NOAH-AFNET 6 trial investigated the use of oral anticoagulation therapy with edoxaban for patients with atrial high-rate episodes (AHREs) but without clinically diagnosed atrial fibrillation (AF). The trial enrolled 2,608 patients and randomly assigned them to receive either edoxaban or placebo. The primary efficacy outcome, which was a composite of cardiovascular death, stroke, or systemic embolism, did not show a significant difference between the two groups. The incidence of stroke was low in both groups. However, the safety outcome, which was a composite of major bleeding or death, occurred more frequently in the edoxaban group. The trial concluded that anticoagulation therapy with edoxaban did not significantly reduce the incidence of cardiovascular death, stroke, or systemic embolism compared to placebo. It also resulted in a higher incidence of major bleeding. The trial suggested that AHREs without clinically diagnosed AF may not require anticoagulation therapy. The trial has limitations such as premature termination and limited diversity in patient population. In summary, the trial did not find a significant benefit of anticoagulation therapy in patients with AHREs but without clinically diagnosed AF and raised concerns about the increased risk of major bleeding with edoxaban.
Keywords
NOAH-AFNET 6 trial
oral anticoagulation therapy
edoxaban
atrial high-rate episodes
clinically diagnosed atrial fibrillation
cardiovascular death
stroke
systemic embolism
placebo
major bleeding
Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy
|
Cookie Declaration
|
Linking Policy
|
Patient Education Disclaimer
|
State Nonprofit Disclosures
|
FAQ
×
Please select your language
1
English